Piramal Pharma Ltd
Piramal Pharma Ltd (PPLPHARMA) last traded at ₹208, a market capitalisation of ₹27,679 crore. Over the past 52 weeks the stock has ranged between ₹132 and ₹220. Piramal Pharma Ltd last reported results for the quarter ended Jun 2026, with sales of ₹2,270 crore and net profit of ₹-69 crore. The next scheduled event is an analyst meet on 2 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Piramal Pharma Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Piramal Pharma Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹2,270 cr, up 17.4% from ₹1,934 cr a year earlier. Net profit was ₹-69 cr, up 15.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 | 2,140 | 2,752 | 2,270 |
| Expenses | 1,900 | 1,866 | 2,193 | 1,827 | 1,885 | 1,944 | 2,291 | 2,075 |
| Operating profit | 342 | 338 | 561 | 107 | 159 | 196 | 461 | 195 |
| OPM % | 15% | 15% | 20% | 6% | 8% | 9% | 17% | 9% |
| Other income | 78 | 29 | 58 | 98 | 80 | 12 | -116 | 109 |
| Interest | 108 | 103 | 104 | 86 | 82 | 89 | 83 | 88 |
| Depreciation | 192 | 197 | 243 | 197 | 203 | 213 | 218 | 224 |
| Profit before tax | 120 | 67 | 273 | -79 | -46 | -94 | 43 | -7 |
| Tax % | 81% | 94% | 44% | 3% | 115% | 45% | 121% | 830% |
| Net profit | 23 | 4 | 154 | -82 | -99 | -136 | -9 | -69 |
| EPS (₹) | 0.17 | 0.03 | 1.16 | -0.61 | -0.75 | -1.02 | -0.07 | -0.52 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Piramal Pharma Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 6,315 | 6,559 | 7,082 | 8,171 | 9,151 | 8,869 | 9,205 |
| Operating profit | 1,428 | 950 | 629 | 1,197 | 1,445 | 922 | 1,010 |
| OPM % | 23% | 14% | 9% | 15% | 16% | 10% | 11% |
| Net profit | 835 | 376 | -186 | 18 | 91 | -326 | -314 |
| EPS (₹) | — | — | -1.41 | 0.13 | 0.69 | -2.45 | -2.36 |
TTM is the trailing twelve months to the most recent quarter.
Piramal Pharma Ltd growth and returns
- 10 Years
- %
- 5 Years
- 7%
- 3 Years
- 8%
- TTM
- 1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -31%
- TTM
- -296%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 29%
- 1 Year
- 10%
- 10 Years
- %
- 5 Years
- 0%
- 3 Years
- -1%
- Last Year
- -4%
Piramal Pharma Ltd shareholding pattern
Promoters held 34.80% at Jun 2026, broadly unchanged since Jun 2025. FIIs 12.51% and DIIs 14.57%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 34.94% | 34.94% | 34.94% | 34.85% | 34.85% | 34.85% | 34.85% | 34.80% |
| FIIs | 31.73% | 31.68% | 31.49% | 30.86% | 30.27% | 29.66% | 30.17% | 12.51% |
| DIIs | 13.80% | 14.09% | 14.78% | 14.25% | 14.89% | 15.68% | 15.61% | 14.57% |
| Public | 19.06% | 18.85% | 18.42% | 19.46% | 19.46% | 19.35% | 19.01% | 37.62% |
| No. of shareholders | 3,59,751 | 4,18,442 | 4,32,843 | 4,58,430 | 4,62,511 | 4,53,830 | 4,50,661 | 4,61,096 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Piramal Pharma Ltd events
The next scheduled event is an analyst meet on 2 Sept 2026.
- Analyst meetSchedule of Analyst/Institutional Investor Meetings
See the full results calendar for every Indian company reporting in the next 30 days.
Piramal Pharma Ltd corporate filings
- Sustainability Report Of Piramal Pharma Limited For The Financial Year 2025-26Company Updatelow impact
Cruxal's analysis: Piramal Pharma Limited has filed its Sustainability Report for the financial year…
Read the full analysis - Announcement under Regulation 30 (LODR)-AcquisitionCompany Updatehigh impact
Cruxal's analysis: Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AGInsider Trading / SASTmedium impact
Cruxal's analysis: Piramal Pharma Limited has seen a reduction in encumbered shares as Deutsche Bank AG…
Read the full analysis - Announcement Under Regulation 30 (LODR)- Exercise Of Call Option For Acquisition Of Additional Equity Stake In Yapan Bio Private LimitedCompany Updatehigh impact
Cruxal's analysis: Piramal Pharma Limited has announced the exercise of a call option to acquire an…
Read the full analysis - Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Piramal Pharma Ltd has issued an intimation regarding scheduled meetings with analysts…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Piramal Pharma Ltd
Cruxal reads every Piramal Pharma Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.